Nektar Therapeutics (NKTR) Gross Profit (2016 - 2025)
Historic Gross Profit for Nektar Therapeutics (NKTR) over the last 16 years, with Q3 2025 value amounting to $1.5 million.
- Nektar Therapeutics' Gross Profit fell 8861.26% to $1.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $16.1 million, marking a year-over-year decrease of 6720.26%. This contributed to the annual value of $56.4 million for FY2024, which is 622.9% up from last year.
- According to the latest figures from Q3 2025, Nektar Therapeutics' Gross Profit is $1.5 million, which was down 8861.26% from $851000.0 recorded in Q2 2025.
- Nektar Therapeutics' Gross Profit's 5-year high stood at $20.7 million during Q2 2021, with a 5-year trough of -$6.8 million in Q1 2025.
- Moreover, its 5-year median value for Gross Profit was $14.5 million (2023), whereas its average is $13.3 million.
- Its Gross Profit has fluctuated over the past 5 years, first soared by 5440.62% in 2024, then plummeted by 16517.16% in 2025.
- Quarter analysis of 5 years shows Nektar Therapeutics' Gross Profit stood at $18.8 million in 2021, then decreased by 16.22% to $15.8 million in 2022, then fell by 15.63% to $13.3 million in 2023, then surged by 54.41% to $20.6 million in 2024, then crashed by 92.74% to $1.5 million in 2025.
- Its Gross Profit was $1.5 million in Q3 2025, compared to $851000.0 in Q2 2025 and -$6.8 million in Q1 2025.